Golden Star Resources Ltd
Change company Symbol lookup
Select an option...
GSS Golden Star Resources Ltd
T AT&T Inc
TBNK Territorial Bancorp Inc
YUM Yum! Brands Inc
RTX Raytheon Technologies Corp
NAKD Naked Brand Group Ltd
FAMI Farmmi Inc
PTPI Petros Pharmaceuticals Inc
ZNGA Zynga Inc
PROG Progenity Inc
Go

Materials : Metals & Mining | Small Cap Value
Based in Canada
Company profile

Golden Star Resources Ltd. is a gold mining and exploration company. The Company, through its subsidiary, Golden Star Limited (Wassa), owns and operates the Wassa underground mine and a carbon-in-leach processing plant located northeast of the town of Tarkwa, Ghana. Its Wassa underground mine is located in south-western Ghana. The Company's segments include Wassa and Exploration. The Company also holds and manages interests in several gold exploration projects in Ghana.

Closing Price
$3.76
Day's Change
0.01 (0.27%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.77
Day's Low
3.75
Volume
(Light)
Volume:
626,721

10-day average volume:
1,606,333
626,721

Gemini Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

7:00 am ET October 14, 2021 (BusinessWire) Print

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced the grant of inducement awards under Gemini's 2021 Inducement Plan to two new employees of options to purchase an aggregate of 217,000 shares of Gemini's common stock. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Gemini's Compensation Committee and made as a material inducement to each employee's entry into employment with Gemini.

The agreements covering these option awards are consistent with Gemini's standard stock option inducement award agreement. Each option has a ten-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the grant date and the remainder in equal monthly installments over the following three years, subject to each employee's continued service with Gemini through the applicable vesting date.

About Gemini Therapeutics

Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD). Gemini's lead candidate, GEM103, is a recombinant form of human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant and a Phase 1/2a study in patients with neovascular age-related macular degeneration with or at risk for macular atrophy. Gemini is also working to advance a potentiating antibody for CFH, GEM307, towards clinical development for treatment of systemic diseases. For more information, visit www.geminitherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005087/en/

SOURCE: Gemini Therapeutics, Inc.

Investor Contact: 
Argot Partners
Sherri Spear
212-600-1902
gemini@argotpartners.com

Media Contact: 
Argot Partners
Joshua R. Mansbach
212-600-1902
gemini@argotpartners.com
comtex tracking

COMTEX_395176473/1006/2021-10-14T07:00:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.